SCHEMBL1975908

SCHEMBL1975908

C=CCCCCCC[C@](C)(N)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 1/20 0.53
ARG2 P78540 1/20 0.53
ACLY P53396 1/20 0.47
MAPT P10636 3/20 0.47
ABCC4 O15439 1/20 0.47
GGT1 P19440 1/20 0.44
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.42
TSHR P16473 1/20 0.39
FFAR1 O14842 1/20 0.35
CPT2 P23786 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ACACB O00763 1/20 0.34
ACACA Q13085 1/20 0.34
LPAR2 Q9HBW0 1/20 0.34
LPAR3 Q9UBY5 1/20 0.34
USP2 O75604 3/20 0.34
CYP3A4 P08684 3/20 0.34
RECQL P46063 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22862319 1.00 ARG1 (0.53) ARG1ARG2ACLYMAPTABCC4
SCHEMBL1976899 1.00 ARG1 (0.53) ARG1ARG2ACLYMAPTABCC4
SCHEMBL19305278 1.00 ARG1 (0.53) ARG1ARG2ACLYMAPTABCC4
SCHEMBL19357334 1.00 ARG1 (0.53) ARG1ARG2ACLYMAPTABCC4
SCHEMBL1975910 1.00 ARG1 (0.53) ARG1ARG2ACLYMAPTABCC4
SCHEMBL18954854 1.00 ARG1 (0.53) ARG1ARG2ACLYMAPTABCC4
SCHEMBL18954850 1.00 ARG1 (0.53) ARG1ARG2ACLYMAPTABCC4
SCHEMBL16401653 0.98 ARG1 (0.55) ARG1ARG2ACLYMAPTABCC4
SCHEMBL18954910 0.98 ARG1 (0.55) ARG1ARG2ACLYMAPTABCC4
SCHEMBL19305277 0.98 ARG1 (0.55) ARG1ARG2ACLYMAPTABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720088-A1 CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS University of Georgia Research Foundation, Inc. (US) 2026-04-08 EP claimed
EP-4713348-A1 DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 University of Georgia Research Foundation, Inc. (US) 2026-03-25 EP claimed
US-12391733-B2 Stapled intracellular-targeting antimicrobial peptides to treat infection DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-08-19 US claimed
WO-2025085624-A1 INHIBITORS OF RAB-RILPL INTERACTIONS AND USES THEREOF UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2025-04-24 WO claimed
US-12264185-B2 Stabilized BCL9 peptides for treatment of aberrant Wnt signaling WNTRX PHARMACEUTICALS INC. (US) 2025-04-01 US claimed
US-20250042961-A1 P53 PEPTIDOMIMETIC MACROCYCLES AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) 2025-02-06 US claimed
WO-2024243509-A1 CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-11-28 WO claimed
EP-4467153-A1 CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS University of Georgia Research Foundation, Inc. (US) 2024-11-27 EP claimed
WO-2024238623-A1 DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-11-21 WO claimed
CN-118829648-A P53 peptidomimetic macrocycles 默沙东有限责任公司 2024-10-22 CN claimed
US-10308684-B2 Cell penetrating stapled peptide, manufacturing method therefor, and use thereof SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2019-06-04 US claimed
US-20190023754-A1 Stabilized BCL9 Peptides for Treatment of Aberrant WNT Signaling WNTRX PHARMACEUTICALS INC. 2019-01-24 US claimed
US-20170342108-A1 CELL PENETRATING STAPLED PEPTIDE, MANUFACTURING METHOD THEREFOR, AND USE THEREOF SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2017-11-30 US claimed
WO-2017062518-A1 STABILIZED BCL9 PEPTIDES FOR TREATMENT OF ABERRANT WNT SIGNALING WNTRX PHARMACEUTICALS INC. (US) 2017-04-13 WO claimed
US-9447156-B2 Methods and compositions for inhibiting neddylation of proteins ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-09-20 US claimed
US-20160046672-A1 STAPLING eIF4E INTERACTING PEPTIDES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-02-18 US claimed
EP-2976354-A1 STAPLING eIF4E INTERACTING PEPTIDES Agency For Science, Technology And Research (SG) 2016-01-27 EP claimed
WO-2014149001-A1 STAPLING eIF4E INTERACTING PEPTIDES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2014-09-25 WO claimed
US-20140179593-A1 METHODS AND COMPOSITIONS FOR INHIBITING NEDDYLATION OF PROTEINS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-06-26 US claimed
WO-2012158789-A2 METHODS AND COMPOSITIONS FOR INHIBITING NEDDYLATION OF PROTEINS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2012-11-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179593-A1 METHODS AND COMPOSITIONS FOR INHIBITING NEDDYLATION OF PROTEINS NEDD8, UBE3C, UBE2M ARG1 3783/4885ARG2 4280/4885ACLY 3438/4885
US-20160046672-A1 STAPLING eIF4E INTERACTING PEPTIDES EIF4EBP1, EIF4E, EIF4G2 ARG1 3514/4885ARG2 3182/4885ACLY 3448/4885
US-12391733-B2 Stapled intracellular-targeting antimicrobial peptides to treat infection VIP, SPPL2B, HM13 ARG1 329/4885ARG2 293/4885ACLY 3331/4885
US-20250042961-A1 P53 PEPTIDOMIMETIC MACROCYCLES TP53, MDM2, MDM4 ARG1 821/4885ARG2 694/4885ACLY 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.